Anxo Pharmaceutical Co., Ltd.(TW:6677)
NT$20.95+0.15 (+0.72%)
TW:6677
Anxo Pharmaceutical Co., Ltd. financials statements
NT$20.95
At close:+0.15 (+0.72%)
Anxo Pharmaceutical Co., Ltd. (6677) Ratios
Anxo Pharmaceutical Co., Ltd. Ratios
TW:6677's free cash flow for Q2 2026 was NT$-55.35M. For the 2026 fiscal year, TW:6677's free cash flow was decreased by NT$-42.80M and operating cash flow was NT$-12.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.57 | 1.75 | 2.01 | 1.39 | 1.49 |
| Quick Ratio | 1.10 | 1.23 | 1.43 | 0.95 | 0.99 |
| Cash Ratio | 0.70 | 0.71 | 0.61 | 0.43 | 0.45 |
| Solvency Ratio | 0.04 | 0.02 | 0.09 | 0.05 | 0.09 |
| Operating Cash Flow Ratio | 0.10 | 0.22 | -0.01 | 0.13 | 0.17 |
| Short-Term Operating Cash Flow Coverage | 0.16 | 0.42 | -0.01 | 0.23 | 0.28 |
| Net Current Asset Value | NT$ -110.76M | NT$ -89.66M | NT$ -37.04M | NT$ -372.98M | NT$ -382.27M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.34 | 0.36 | 0.45 | 0.46 |
| Debt-to-Equity Ratio | 0.74 | 0.71 | 0.72 | 1.23 | 1.21 |
| Debt-to-Capital Ratio | 0.43 | 0.42 | 0.42 | 0.55 | 0.55 |
| Long-Term Debt-to-Capital Ratio | 0.28 | 0.30 | 0.31 | 0.42 | 0.44 |
| Financial Leverage Ratio | 2.08 | 2.06 | 2.04 | 2.72 | 2.62 |
| Debt Service Coverage Ratio | 0.12 | 0.14 | 0.42 | 0.25 | 0.36 |
| Interest Coverage Ratio | -2.63 | -3.38 | 2.94 | 0.39 | 3.14 |
| Debt to Market Cap | 0.69 | 0.53 | 0.31 | 0.61 | 0.72 |
| Interest Debt Per Share | 13.43 | 13.34 | 15.85 | 18.75 | 17.95 |
| Net Debt to EBITDA | 10.99 | 11.02 | 3.75 | 7.61 | 6.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 35.60% | 36.35% | 42.23% | 38.26% | 40.24% |
| EBIT Margin | -5.18% | -4.84% | 6.04% | 1.21% | 4.50% |
| EBITDA Margin | 3.86% | 3.73% | 13.97% | 9.81% | 13.50% |
| Operating Profit Margin | -5.18% | -6.30% | 5.65% | 0.69% | 4.87% |
| Pretax Profit Margin | -5.41% | -6.70% | 4.12% | -0.54% | 2.95% |
| Net Profit Margin | -4.05% | -6.39% | 2.33% | -1.45% | 2.33% |
| Continuous Operations Profit Margin | -4.17% | -6.04% | 3.28% | -0.81% | 2.40% |
| Net Income Per EBT | 74.86% | 95.31% | 56.52% | 266.40% | 79.06% |
| EBT Per EBIT | 104.36% | 106.37% | 72.77% | -79.29% | 60.67% |
| Return on Assets (ROA) | -1.65% | -2.71% | 0.99% | -0.64% | 1.00% |
| Return on Equity (ROE) | -3.44% | -5.60% | 2.01% | -1.73% | 2.62% |
| Return on Capital Employed (ROCE) | -2.86% | -3.52% | 3.07% | 0.42% | 2.77% |
| Return on Invested Capital (ROIC) | -1.80% | -2.70% | 2.10% | 0.34% | 1.88% |
| Return on Tangible Assets | -1.69% | -2.78% | 1.00% | -0.65% | 1.02% |
| Earnings Yield | -3.25% | -4.28% | 0.89% | -0.91% | 1.62% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.49 | 4.21 | 3.60 | 3.44 | 3.80 |
| Payables Turnover | 9.23 | 7.61 | 7.41 | 5.75 | 6.36 |
| Inventory Turnover | 2.14 | 2.17 | 1.91 | 2.20 | 2.06 |
| Fixed Asset Turnover | 0.83 | 0.86 | 0.87 | 0.78 | 0.72 |
| Asset Turnover | 0.41 | 0.42 | 0.42 | 0.44 | 0.43 |
| Working Capital Turnover Ratio | 2.46 | 2.06 | 2.66 | 3.86 | 3.50 |
| Cash Conversion Cycle | 212.26 | 206.81 | 242.96 | 208.36 | 215.77 |
| Days of Sales Outstanding | 81.23 | 86.67 | 101.38 | 105.96 | 96.12 |
| Days of Inventory Outstanding | 170.59 | 168.09 | 190.81 | 165.91 | 177.06 |
| Days of Payables Outstanding | 39.56 | 47.94 | 49.23 | 63.52 | 57.42 |
| Operating Cycle | 251.82 | 254.75 | 292.18 | 271.87 | 273.19 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.99 | 2.01 | -0.05 | 1.48 | 1.57 |
| Free Cash Flow Per Share | 0.14 | 0.92 | -1.19 | 1.13 | 0.89 |
| Dividend Paid and CapEx Coverage Ratio | 1.16 | 1.35 | -0.05 | 4.29 | 2.31 |
| Capital Expenditure Coverage Ratio | 1.16 | 1.85 | -0.05 | 4.29 | 2.31 |
| Operating Cash Flow Coverage Ratio | 0.08 | 0.15 | -0.00 | 0.08 | 0.09 |
| Operating Cash Flow to Sales Ratio | 0.07 | 0.13 | -0.00 | 0.08 | 0.10 |
| Free Cash Flow Yield | 0.74% | 3.84% | -2.46% | 3.97% | 3.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -30.74 | -23.30 | 112.67 | -109.81 | 60.85 |
| Price-to-Sales (P/S) Ratio | 1.24 | 1.49 | 2.62 | 1.59 | 1.44 |
| Price-to-Book (P/B) Ratio | 1.06 | 1.31 | 2.26 | 1.90 | 1.62 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 135.57 | 26.03 | -40.58 | 25.16 | 26.66 |
| Price-to-Operating Cash Flow Ratio | 18.91 | 11.94 | -927.75 | 19.29 | 15.12 |
| Price-to-Earnings Growth (PEG) Ratio | 0.75 | 0.07 | -0.42 | 0.66 | -1.60 |
| Enterprise Value Multiple | 43.26 | 51.10 | 22.51 | 23.80 | 16.67 |
| Enterprise Value | 1.41B | 1.71B | 2.96B | 2.02B | 1.85B |
| EV to EBITDA | 43.26 | 51.10 | 22.51 | 23.80 | 16.67 |
| EV to Sales | 1.67 | 1.90 | 3.14 | 2.33 | 2.25 |
| EV to Free Cash Flow | 181.75 | 33.19 | -48.69 | 37.00 | 41.71 |
| EV to Operating Cash Flow | 25.35 | 15.23 | -1113.21 | 28.37 | 23.67 |
| Tangible Book Value Per Share | 19.01 | 19.61 | 22.87 | 16.36 | 15.84 |
| Shareholders’ Equity Per Share | 17.72 | 18.35 | 21.43 | 15.05 | 14.68 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.10 | 0.20 | -0.49 | 0.19 |
| Revenue Per Share | 15.07 | 16.07 | 18.49 | 17.99 | 16.50 |
| Net Income Per Share | -0.61 | -1.03 | 0.43 | -0.26 | 0.39 |
| Tax Burden | 0.75 | 0.95 | 0.57 | 2.66 | 0.79 |
| Interest Burden | 1.04 | 1.38 | 0.68 | -0.45 | 0.66 |
| Research & Development to Revenue | 0.16 | 0.17 | 0.15 | 0.16 | 0.14 |
| SG&A to Revenue | 0.25 | 0.26 | 0.22 | 0.21 | 0.22 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Income Quality | -1.63 | -1.87 | -0.12 | -5.68 | 4.07 |
Currency in TWD
